#NEMIO , a randomized phase I-II trial: Durvalumab +/- tremelimumab in combination with dose-dense MVAC as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma. Presented by Constance Thibault Hôpital européen Georges-Pompidou AP-HP. #ESMO23 coverage by Rashid K. Sayyid > bit.ly/471gbmI

Constance Thibault reported the GETUG of nemio trial (MVAC + durva +/- treme) in neoadj. Data that deserve confirmation. Ph3 testing chemo + IO ongoing

Membres #AFU : retrouvez demain à 19h30 un canal AFU dédié à la cystectomie abordant immunothérapie & nouvelles imageries #urologie #vessie .
Avec Yann NEUZILLET Constance Thibault Thomas Seisen

Merci à notre partenaire Merck France

Should we be using video-recorded cystoscopy for blinded independent central review of tumor response in Open-label NMIBC Trials?

Benjamin Pradere Morgan Roupret Thomas Seisen joaquim bellmunt European Urology #bladdercancer

sciencedirect.com/science/articl…

Hard work by the panel in Paris. Interesting and important changes for the 2024 NMIBC and UTUC EAU Guidelines. #eau

And a great diner organized by our local 🇫🇷members Evanguelos Xylinas Thomas Seisen Alex Masson-Lecomte 🙏🙏🙏

European Association of Urology (EAU) #eauguidelines meeting for #nmibc #utuc such a great team enjoying Paris after an insightful meeting!
Great time-Great thoughts-Great Friends
The perfect combo to work during July

Alex Masson-Lecomte Paolo Gontero

Current Issue: First-line Intravesical Chemotherapy for Non–muscle-invasive Bladder Cancer: Chimera or “Ne Plus Ultra”?

buff.ly/44P1fGW

Louis Lenfant Ugo Pinar Morgan Roupret Thomas Seisen

#bladdercancer #medtwitter

Great presentation by Paolo Gontero on the collaborative effort on BCG Failure by European Association of Urology (EAU) guidelines NMIBC Panel

🤩Stellar presentation by Ugo Pinar about long term of adjustable ACT balloon at the #EAU23
Main results at 5 years:
-62% continence
-20% erosion
Strong study with long FU

chartier-kastler e Morgan Roupret Thomas Seisen Hôpital Pitié Salpêtrière - AP-HP @MedecineSU ruggiero marina

Day 2 of #EAU23 was filled with excellent presentations from pioneers in the field of bladder cancer and UTUC. Informative and inspiring! Ashish M. Kamat, MD, MBBS 💙alison birtle Thomas Seisen Arnulf Stenzl Shahrokh F. Shariat jim catto Morgan Roupret Tahlita Zuiverloon MD PhD and more...European Association of Urology (EAU)

State-of-the-Art Lecture: Evidence for neoadjuvant treatment before radical nephroureterectomy. Presented by Thomas Seisen Hôpital Pitié Salpêtrière - AP-HP. #EAU23 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3YVg2Nj European Association of Urology (EAU)

On the heals of the Journal of Clinical Oncology Coleman et al. NAC in UTUC trial published earlier this year, Thomas Seisen highlighting the phase 2 iNDUCT at #EAU23

UroToday.com

This month in JU: Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis
auajournals.org/stoken/default…

🆕Article
Assessment of the Ecological Association between #TobaccoSmoking Exposure and #BladderCancer Incidence over the Past Half-Century in the United States
by Thomas Seisen, Muhieddine Labban et al

👉mdpi.com/1718-7729/30/2…

Robotic vs open cystectomy with ileal conduit for the management of neurogenic bladder: a comparative study. #BeyondTheAbstract on UroToday > bit.ly/3QkKnlK Ugo Pinar Morgan Roupret Véronique Phé Christophe Vaessen chartier-kastler e Thomas Seisen @WJUrol

Hot off the press in Current Oncology!🔥

An ecological study in 🇺🇸 examining the association between trends in #tobacco smoking prevalence 🚬 and bladder versus lung #Cancer incidence

➡️Check out the full paper mdpi.com/1718-7729/30/2…

Brigham and Women's Hospital Department of Urology Dana-Farber Lank Center for Genitourinary Oncology CSPH

Huge congratulations to Quoc-Dien Trinh, MD, MBA for his DOD Health Disparity Research Award recommended for funding this week.

Continuing to forge a path for high-impact disparities research.

Prostate Cancer Foundation Amer. Urol. Assn. ACS New England Adam Kibel Toni Choueiri, MD CSPH Dana-Farber Lank Center for Genitourinary Oncology

🚨❓Are we ready for the routine omission of systematic biopsy for patients with positive MRI as supported by Jonas Hugosson et al. in the NEJM ?

👉our answer in European Urology Oncology
tinyurl.com/24um29m2

with Thomas Seisen

Original NEJM paper : tinyurl.com/usvkdtvj
1/2

Robotic vs open cystectomy with ileal conduit for the management of neurogenic bladder: a comparative study. #BeyondTheAbstract on UroToday > bit.ly/3QkKnlK Ugo Pinar Morgan Roupret Véronique Phé Christophe Vaessen chartier-kastler e Thomas Seisen @WJUrol